- Atossa Therapeutics (ATOS -2.4%) has completed the enrollment of 32 healthy adult volunteers in an Australia-based Phase 1 study evaluating the safety and tolerability of a nasal spray formulation of AT-301, in development for the potential treatment of non-hospitalized people with COVID-19.
- A Phase 2 study should launch in H1 2021.
- https://seekingalpha.com/news/3623287-atossa-advances-study-of-covidminus-19-nasal-spray
Monday, October 19, 2020
Atossa advances study of COVID-19 nasal spra
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.